ImmPort Study ID	PubMed	Study Title	PI	Biosample ID	Experiment ID	Cohort	Repository Accession	Type	Subtype	Biosample Name	Biosample Description	Species	Strain	Cancer Type	Tissue	Cell Type	Cell Line	Treatment
GSE87424	28108460	Enhancer Remodeling During Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacological Targeting of the P-TEFb Complex	Gary L. Johnson Lab	SRX2194329	GSE87424	HCC1806 breast carcinoma cell line	GSM2330622	Breast Cancer	Invasive Breast Carcinoma (BRCA)	Figure3_HCC1806_10nMtrametinib300nMJQ1_48h	Figure3_HCC1806_normalizedRSEM.xlsx	Homo sapiens	Figure3_HCC1806_10nMtrametinib300nMJQ1_48h	Breast Cancer	None	None	cell line: SUM229 breast carcinoma cell line, EpCAM/CD49f positive subpopulation	DMSO
GSE87424	28108460	Enhancer Remodeling During Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacological Targeting of the P-TEFb Complex	Gary L. Johnson Lab	SRX2194326	GSE87424	HCC1806 breast carcinoma cell line	GSM2330623	Breast Cancer	Invasive Breast Carcinoma (BRCA)	Figure3_HCC1806_DMSO_48h	Figure3_HCC1806_normalizedRSEM.xlsx	Homo sapiens	Figure3_HCC1806_DMSO_48h	Breast Cancer	None	None	cell line: SUM229 breast carcinoma cell line, EpCAM/CD49f positive subpopulation	30nM trametinib
GSE87424	28108460	Enhancer Remodeling During Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacological Targeting of the P-TEFb Complex	Gary L. Johnson Lab	SRX2194327	GSE87424	HCC1806 breast carcinoma cell line	GSM2330624	Breast Cancer	Invasive Breast Carcinoma (BRCA)	Figure3_HCC1806_10nMtrametinib_48h	Figure3_HCC1806_normalizedRSEM.xlsx	Homo sapiens	Figure3_HCC1806_10nMtrametinib_48h	Breast Cancer	None	None	cell line: SUM229 breast carcinoma cell line, EpCAM/CD49f negative subpopulation	DMSO
GSE87424	28108460	Enhancer Remodeling During Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacological Targeting of the P-TEFb Complex	Gary L. Johnson Lab	SRX2194307	GSE87424	EpCAM/CD49f positive SUM229 breast carcinoma subpopulation	GSM2330625	Breast Cancer	Invasive Breast Carcinoma (BRCA)	SUM229pos_30nMtrametinib_24h		Homo sapiens	SUM229pos_30nMtrametinib_24h	Breast Cancer	None	None	cell line: SUM229 breast carcinoma cell line, EpCAM/CD49f negative subpopulation	30nM trametinib
GSE87424	28108460	Enhancer Remodeling During Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacological Targeting of the P-TEFb Complex	Gary L. Johnson Lab	SRX2194308	GSE87424	EpCAM/CD49f negative SUM229 breast carcinoma subpopulation	GSM2330642	Breast Cancer	Invasive Breast Carcinoma (BRCA)	SUM229neg_DMSO_24h		Homo sapiens	SUM229neg_DMSO_24h	Breast Cancer	None	None	cell line: HCC1806 breast carcinoma cell line	DMSO
GSE87424	28108460	Enhancer Remodeling During Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacological Targeting of the P-TEFb Complex	Gary L. Johnson Lab	SRX2194306	GSE87424	EpCAM/CD49f positive SUM229 breast carcinoma subpopulation	GSM2330643	Breast Cancer	Invasive Breast Carcinoma (BRCA)	SUM229pos_DMSO_24h		Homo sapiens	SUM229pos_DMSO_24h	Breast Cancer	None	None	cell line: HCC1806 breast carcinoma cell line	10nM trametinib
GSE87424	28108460	Enhancer Remodeling During Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacological Targeting of the P-TEFb Complex	Gary L. Johnson Lab	SRX2194314	GSE87424	SUM159 breast carcinoma cell line	GSM2330644	Breast Cancer	Invasive Breast Carcinoma (BRCA)	SUM159_DMSO_24h_replicate1	DESeq2_SUM159replicates.xlsx	Homo sapiens	SUM159_DMSO_24h_replicate1	Breast Cancer	None	None	cell line: HCC1806 breast carcinoma cell line	300nM JQ1
GSE87424	28108460	Enhancer Remodeling During Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacological Targeting of the P-TEFb Complex	Gary L. Johnson Lab	SRX2194315	GSE87424	SUM159 breast carcinoma cell line	GSM2330645	Breast Cancer	Invasive Breast Carcinoma (BRCA)	SUM159_100nM_trametinib_24h_replicate1	DESeq2_SUM159replicates.xlsx	Homo sapiens	SUM159_100nM_trametinib_24h_replicate1	Breast Cancer	None	None	cell line: HCC1806 breast carcinoma cell line	10nM trametinib 300nM JQ1
GSE87424	28108460	Enhancer Remodeling During Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacological Targeting of the P-TEFb Complex	Gary L. Johnson Lab	SRX2194310	GSE87424	T11 orthotopic serial transplant cell line	GSM2330626	Breast Cancer	Invasive Breast Carcinoma (BRCA)	T11_DMSO_24h		Mus musculus	T11_DMSO_24h	Breast Cancer	None	None	cell line: T11 orthotopic serial transplant cell line	DMSO
GSE87424	28108460	Enhancer Remodeling During Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacological Targeting of the P-TEFb Complex	Gary L. Johnson Lab	SRX2194311	GSE87424	T11 orthotopic serial transplant cell line	GSM2330627	Breast Cancer	Invasive Breast Carcinoma (BRCA)	T11_500nMtrametinib_24h		Mus musculus	T11_500nMtrametinib_24h	Breast Cancer	None	None	cell line: T11 orthotopic serial transplant cell line	500nM trametinib
GSE87424	28108460	Enhancer Remodeling During Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacological Targeting of the P-TEFb Complex	Gary L. Johnson Lab	SRX2194312	GSE87424	C3TAg GEMM cell line	GSM2330628	Breast Cancer	Invasive Breast Carcinoma (BRCA)	C3TAgT2_DMSO_24h		Mus musculus	C3TAgT2_DMSO_24h	Breast Cancer	None	None	cell line: C3TAg GEMM cell line	DMSO
GSE87424	28108460	Enhancer Remodeling During Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacological Targeting of the P-TEFb Complex	Gary L. Johnson Lab	SRX2194313	GSE87424	C3TAg GEMM cell line	GSM2330629	Breast Cancer	Invasive Breast Carcinoma (BRCA)	C3TAgT2_500nMtrametinib_24h		Mus musculus	C3TAgT2_500nMtrametinib_24h	Breast Cancer	None	None	cell line: C3TAg GEMM cell line	500nM trametinib
